Meridian Bioscience Inc

Meridian Bioscience — FY2020 Earnings Presentation

16 slides from Meridian Bioscience's earnings presentation, Nov 13, 2020

  1. Slide 1: FY2020 Q4 & Full Year Results

    Exhibit 99.2 FY2020 Q4 & Full Year Results November 13, 2020Exhibit 99.2 FY2020 Q4 & Full Year Results November 13, 2020

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within

  3. Slide 3: Non-GAAP Financial Measures

    Non-GAAP Financial Measures Certain financial measures presented in this presentation, such as operating expenses, operating income, operating margin, net earnings and earnings per diluted share, each on an adjusted basis, excluding as applicable the effects of acquisition-related costs, changes in

  4. Slide 4: FY2020 Business Highlights

    FY2020 Business Highlights • Raised guidance twice & exceeded on all metrics • Life Science rapid growth & Diagnostics moderately down due to pandemic • Closed acquisition of Exalenz & advanced integration • Launched Curian & HpSA assay, plus 50+ new Life Science products Diagnostics Life ScienceFY2

  5. Slide 5: Full Year Earnings Summary

    FY2020 Full Year Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2020 FY2019 Change Highlights Revenue $253,667 $201,014 +26% • Record revenues and earnings Gross Margin % 62% 59% +3 pts • Life Science revenues doubled driven (1) Operating expenses $94,560 $79,799 +18% by re

  6. Slide 6: Full Year Operating Segment Highlights

    FY2020 Full Year Operating Segment Highlights ($000’s) Life Science Diagnostics FY2020 FY2019 Change FY2020 FY2019 Change (Adjusted Non-GAAP) (Adjusted Non-GAAP) Revenue $121,132 $136,682 -11% Revenue $132,535 $64,332 +106% Operating income $1,969 $28,836 -93% Operating income $69,026 $17,769 +288%

  7. Slide 7: Full Year COVID-19 Product Contribution

    FY2020 Full Year COVID-19 Product Contribution ($000’s) Life Science Q1 Q2 Q3 Q4 FY2020 COVID-19 reagents revenue $ - $5,600 $47,800 $18,100 $71,500 % of Total Life Science Revenue NA 25% 76% 53% 54% Life Science COVID-19 revenue by: Technology: Molecular reagents $ - $5,600 $32,000 $14,600 $52,200

  8. Slide 8: Q4 FY2020 Business Highlights

    Q4 FY2020 Business Highlights • Demand for Life Science COVID-19 reagents remains strong • Diagnostics sees strong rebound over Q3 • Diagnostics clinical trials re-start, but still not to expectations ® • Locked design of Revogene COVID-19 assay and preparing EUA submission for the FDA Diagnostics L

  9. Slide 9: Fourth Quarter Earnings Summary

    FY2020 Fourth Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2020 FY2019 Change Highlights Revenue $64,153 $50,846 +26% • Revenues reflect solid COVID-19 contribution Gross Margin % 60% 57% +3 pts from Life Science and progress towards (1) Operating expenses $26,302

  10. Slide 10: Fourth Quarter Operating Segment Highlights

    FY2020 Fourth Quarter Operating Segment Highlights ($000’s) Life Science Diagnostics FY2020 FY2019 Change FY2020 FY2019 Change (Adjusted Non-GAAP) (Adjusted Non-GAAP) Revenue $29,801 $33,399 -11% Revenue $34,352 $17,447 +97% Operating income ($2,515) $3,955 NMF Operating income $17,239 $5,170 +233%

  11. Slide 11: FY2021 Fiscal Year Guidance

    FY2021 Fiscal Year Guidance Meridian Bioscience Consolidated net revenues: $290 to $310 million Adjusted operating margin: 23.5% to 24.5% Tax Rate: 23% to 24% Adjusted earnings per share*: $1.14 to $1.28 Diagnostics Life Science Net revenues: $140 to $150 million Net revenues: $150 to $160 million *

  12. Slide 12: Meridian Growth Trends

    Meridian Growth Trends ($ in millions) Net Revenue Cash from Operations $300 $254 $214 $155 Life Science $201 $133 $63 $64 $48 $36 $35 $150 Diagnostics $145 $137 $121 (1) (2) (3) FY18 FY19 FY20 FY21E FY18 FY19 FY20 FY21E (1) Total does not sum due to rounding (2) Reflects the mid-point of the guidan

  13. Slide 13: COVID-19 Shots on Goal

    COVID-19 Shots on Goal DIAGNOSTICS LIFE SCIENCE For Tests to check for For Tests to check for SARS-CoV-2 Virus SARS-CoV-2 Antibodies Spike proteins Nucleocapsid ® Revogene SARS-CoV-2 Rapid Ag Immunoassay Reagent Master Mixes SARS-CoV-2 Antibody Pairs Recombinant Antigens (Working Towards EUA) (CE Ma

  14. Slide 14: Growth Drivers Post-COVID

    Growth Drivers Post-COVID Life Science Diagnostics Menu expansion on four platforms Product Innovation Grow share in Leverage fully staffed Performance & Build off new and stronger H. pylori commercial organization Quality second IVD relationships from serology testing to noneGrowth Drivers Post-COV

  15. Slide 15: Diagnostics R&D Pipeline

    Diagnostics R&D Pipeline (as of 9/30/2020) Expected FY21 Development Feasibility Clinicals FDA FDA Submissions Liver MBT PMA Breath C. difficile Streptococcus Shiga Toxin C. difficile Campylobacter pneumoniae / Campylobacter Immunoassay Legionella COVID-19 EUA RI Panel COVID-19 EUA Molecular RI Pane

  16. Slide 16: Contact

    Contact: [email protected]: [email protected]

Meridian Bioscience — FY2020 Earnings Presentation on 6ix